Key terms
About BBIO
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BBIO news
Apr 08
5:46am ET
Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes
Mar 24
9:47pm ET
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
Mar 21
4:45am ET
BridgeBio assumed with an Outperform at Raymond James
Mar 20
7:32am ET
BridgeBio reports inducement grants under Nasdaq listing rule
Mar 20
6:10am ET
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)
Mar 20
5:55am ET
BridgeBio price target raised to $45 from $35 at JPMorgan
Mar 19
7:34am ET
BridgeBio price target raised to $70 from $60 at Cantor Fitzgerald
Mar 18
10:55am ET
BridgeBio participates in a conference call with Cantor Fitzgerald
Mar 18
9:48am ET
BridgeBio participates in a conference call with Cantor Fitzgerald
Mar 06
11:20pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 06
6:22am ET
BridgeBio 8.6M share Secondary priced at $29.00
Mar 05
6:35am ET
BridgeBio price target lowered to $53 from $60 at Mizuho
Mar 05
5:12am ET
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)
Mar 05
5:01am ET
Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)
Mar 04
7:06pm ET
Buy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial Outlook
Mar 04
4:18pm ET
BridgeBio announces $250M common stock offering
Mar 04
2:25pm ET
Maintained Buy Rating for BridgeBio Pharma Amidst Strategic Partnerships and Market Growth Potential
Mar 04
5:18am ET
BridgeBio, Bayer announce European licensing agreement for acoramidis
Feb 29
6:26am ET
Optimistic Buy Rating for BridgeBio Pharma Amid Strong Market Position and Promising Treatment Pipeline
Feb 25
11:30pm ET
Buy Rating Affirmed for BridgeBio Pharma on Strong Clinical Progress and Strategic Financial Positioning
Feb 23
7:29am ET
BridgeBio Pharma: Hold Rating Amidst Uncertainties in Product Launch and Market Dynamics
Feb 23
6:45am ET
BridgeBio price target raised to $46 from $42 at Citi
Feb 23
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 23
5:59am ET
BridgeBio Pharma Poised for Growth: Anticipating Positive Trial Outcomes and Strong Market Potential for Acora
Feb 22
4:35pm ET
Buy Rating Affirmed for BridgeBio Pharma Amidst Strong Acoramidis Prospects and Promising Pipeline Developments
Feb 22
7:34am ET
BridgeBio reports Q4 EPS (96c), consensus (91c)
Feb 15
1:36am ET
Optimistic Outlook: A Buy Rating for BridgeBio Pharma Amidst Regulatory Approvals and a Strong Pipeline
Feb 09
1:20am ET
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), CVS Health (CVS) and BridgeBio Pharma (BBIO)
Feb 09
1:02am ET
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BridgeBio Pharma (BBIO)
Feb 08
6:20am ET
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME)
No recent press releases are available for BBIO
BBIO Financials
Key terms
Ad Feedback
BBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
